Targacept has announced that AstraZeneca will pursue the development of the company’s candidate AZD1446 as a treatment for Alzheimer’s disease.

AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor developed through a research collaboration conducted by Targacept and AstraZeneca.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Under the terms of a 2005 collaborative research and license agreement, AstraZeneca took responsibility for further development and potential commercialisation of AZD1446.

The drug will now move into a Phase II trial as an additional treatment to donepezil for patients with mild to moderate Alzheimer’s.

Targacept President and CEO J Donald deBethizy said that the planned evaluation of AZD1446 as an augmentation treatment in Alzheimer’s complements Targacept’s ongoing Phase IIb study of AZD3480 as a monotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now